Today we had our manuscript on the pre-protein convertase subtilisin kexin (PCSK)-9 approach to the treatment of hyperlipidaemia published. PCSK-9 is a newly discovered protein involved in intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. For some time, we have known that autosomal dominant activating mutations in PCSK-9 cause familial hypercholesterolaemia whereas inactivating mutations in man reduce LDL cholesterol (LDL-C) and are associated with a decreased lifetime risk of cardiovascular events. Clearly, this identifies a potential target for a new therapeutic approach to hypercholesterolaemia.
Based on in vitro and in vivo data antibodies targeting PCSK-9 have emerged as a novel treatment option in patients with cardiovascular disease. We have reviewed how several approaches involving small molecule or peptide inhibition of binding, antibody-mediated inactivation of binding and the use of antisense oligonucleotides are being investigated as therapeutic approaches to lower LDL-C in man.
Until 2011 the literature had been relatively quiet on the advancement of this new treatment paradigm. Our article reviews the biochemistry and physiology of PCSK-9 and details the efforts made to design novel molecules with the ability to inhibit PCSK-9 activity [1]. The potential therapeutic benefits have been investigated in animal models, which has confirmed that reducing PCSK-9 expression can reduce atherosclerosis in mice, rats and primates. Monoclonal antibodies such as REGN-727 and AMG-145 have been shown to reduce LDL-C in patients with familial hypercholesterolaemia already treated with statins or healthy normocholesterolaemic controls. Potential benefits to be gained from PCSK-9's include:
Our timely literature review highlights how PCSK-9 inhibition is a potentially interesting novel addition to the armamentarium of LDL-C reducing drugs. Its effects in reducing LDL-C will need to be confirmed to reduce CVD events in large-scale clinical trials.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Paraskevidekatriaphobia is a phobia of Friday the 13th. Yes, they actually gave it a name.
Yes, it’s Star Wars Day again! The Star Wars films base their wow-factor on their adoption of science
ive years ago I was lucky enough to be involved in a project that resulted in publications
I've been studying medicine for 40 years, and it's beginning to look like something out of science fiction
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
I have never been great at conferences. People don’t believe me but I am painfully shy and far too worried about what.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
In the past, Halloween has meant the end of the crop and the start of the dark, cold winter.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Congratulations class of 2024. That was all I needed to hear when I stood in your shoes almost 40 years ago. 40 years
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
